A new modality for the treatment of cancer
Vyriad has a broad portfolio of oncolytic viruses in discovery, translational and clinical phases of development. Vyriad’s VSV and MV clinical development programs are designed to establish mechanistic and clinical proof of concept for oncolytic virotherapies as a monotherapy or in combination with immune checkpoint inhibitors.
Our oncolytic virotherapies are uniquely trackable using novel biomarkers to guide the intelligent development and clinical validation of virus-drug combination regimens. In parallel, we are developing theranostics and algorithms to predict the best possible treatment regimens for patients.
A series of Phase 1 and 2 clinical studies are ongoing in multiple cancer indications. These trials are being conducted in partnership with leading pharmaceutical companies and top medical research centers, including Vyriad’s founding academic partners, Mayo Clinic and University of Miami.